Switch theme
Sign up to access all valuation multiples
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
2018
70
LTM Revenue $10.6M
Last FY EBITDA -$86.5M
-$97.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aligos Therapeutics has a last 12-month revenue (LTM) of $10.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aligos Therapeutics achieved revenue of $3.9M and an EBITDA of -$86.5M.
Aligos Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aligos Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.6M | XXX | $3.9M | XXX | XXX | XXX |
| Gross Profit | $10.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$86.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2193% | XXX | XXX | XXX |
| EBIT | -$81.3M | XXX | -$89.2M | XXX | XXX | XXX |
| EBIT Margin | -764% | XXX | -2260% | XXX | XXX | XXX |
| Net Profit | -$86.0M | XXX | -$131M | XXX | XXX | XXX |
| Net Margin | -807% | XXX | -3326% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aligos Therapeutics's stock price is $5.
Aligos Therapeutics has current market cap of $32.4M, and EV of -$97.5M.
See Aligos Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$97.5M | $32.4M | XXX | XXX | XXX | XXX | $-15.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aligos Therapeutics has market cap of $32.4M and EV of -$97.5M.
Aligos Therapeutics's trades at -24.7x EV/Revenue multiple, and 1.1x EV/EBITDA.
Equity research analysts estimate Aligos Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aligos Therapeutics has a P/E ratio of -0.4x.
See valuation multiples for Aligos Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.4M | XXX | $32.4M | XXX | XXX | XXX |
| EV (current) | -$97.5M | XXX | -$97.5M | XXX | XXX | XXX |
| EV/Revenue | -9.2x | XXX | -24.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBIT | 1.2x | XXX | 1.1x | XXX | XXX | XXX |
| EV/Gross Profit | -9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAligos Therapeutics's last 12 month revenue growth is 22%
Aligos Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Aligos Therapeutics's rule of 40 is -526% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aligos Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aligos Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2193% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -526% | XXX | -2172% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1781% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2360% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aligos Therapeutics acquired XXX companies to date.
Last acquisition by Aligos Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aligos Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aligos Therapeutics founded? | Aligos Therapeutics was founded in 2018. |
| Where is Aligos Therapeutics headquartered? | Aligos Therapeutics is headquartered in United States of America. |
| How many employees does Aligos Therapeutics have? | As of today, Aligos Therapeutics has 70 employees. |
| Who is the CEO of Aligos Therapeutics? | Aligos Therapeutics's CEO is Dr. Lawrence M. Blatt,PhD. |
| Is Aligos Therapeutics publicy listed? | Yes, Aligos Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aligos Therapeutics? | Aligos Therapeutics trades under ALGS ticker. |
| When did Aligos Therapeutics go public? | Aligos Therapeutics went public in 2020. |
| Who are competitors of Aligos Therapeutics? | Similar companies to Aligos Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aligos Therapeutics? | Aligos Therapeutics's current market cap is $32.4M |
| What is the current revenue of Aligos Therapeutics? | Aligos Therapeutics's last 12 months revenue is $10.6M. |
| What is the current revenue growth of Aligos Therapeutics? | Aligos Therapeutics revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Aligos Therapeutics? | Current revenue multiple of Aligos Therapeutics is -9.2x. |
| Is Aligos Therapeutics profitable? | Yes, Aligos Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
